Maze Therapeutics at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Maze Therapeutics at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Maze Therapeutics South San Francisco, California	1 Associate Director
mazetx.com\|LinkedIn Public company~141 people Clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases. Added two new board members, Paula Johnson and Sophie Kornowski, strengthening governance as it advances precision-medicine programs. › Added two new board members, Paula Johnson and Sophie Kornowski, strengthening governance as it advances precision-medicine programs. 2026-08 · source Added BridgeBio founder and CEO Neil Kumar to its board, bringing rare-disease industry experience to its leadership. 2026-03 · source Appointed Misbah Tahir as chief financial officer, a leadership change ahead of any future fundraising or public offering. 2025-09 · source Source: company newsroom Q2 2026 license revenue $0; H1 2026 was $20M › No revenue in the same 2025 periods; no forward revenue guidance was stated. · 2026-08-11 “No license revenue and $20.0 million in license revenue was recognized for the three and six months ended June 30, 2026, respectively / no license revenue was recognized for the same periods in 2025.” Source: results release	Poster Wed Oct 21 2:30 pm Part of Complex Traits and Polygenic Disorders Poster Wednesday Session First GWAS of kidney function decline identifies 14 significant loci in the Kaiser Permanente Research Bank Exhibit & Poster Hall · Board 8240W Collaborators: Kaiser Permanente Electronic health recordsGenitourinary systemGenome-wide association studyGenomics

Organization

ASHG 2026 Attendance

Maze Therapeutics

South San Francisco, California

1 Associate Director

mazetx.com|LinkedIn

Public company~141 people

Clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases.

Added two new board members, Paula Johnson and Sophie Kornowski, strengthening governance as it advances precision-medicine programs.

›

Added two new board members, Paula Johnson and Sophie Kornowski, strengthening governance as it advances precision-medicine programs.

2026-08 · source

Added BridgeBio founder and CEO Neil Kumar to its board, bringing rare-disease industry experience to its leadership.

2026-03 · source

Appointed Misbah Tahir as chief financial officer, a leadership change ahead of any future fundraising or public offering.

2025-09 · source

Source: company newsroom

Q2 2026 license revenue $0; H1 2026 was $20M

›

No revenue in the same 2025 periods; no forward revenue guidance was stated. · 2026-08-11

“No license revenue and $20.0 million in license revenue was recognized for the three and six months ended June 30, 2026, respectively / no license revenue was recognized for the same periods in 2025.”

Source: results release

Poster

Wed Oct 21
2:30 pm

Part of Complex Traits and Polygenic Disorders Poster Wednesday Session

First GWAS of kidney function decline identifies 14 significant loci in the Kaiser Permanente Research Bank

Exhibit & Poster Hall · Board 8240W

Collaborators: Kaiser Permanente

Electronic health recordsGenitourinary systemGenome-wide association studyGenomics